Altimmune's Pemvidutide Shows Strong Efficacy in Alcohol Use Disorder Trial — Altimmune, Inc.

Event summary

Altimmune's Phase 2 RECLAIM trial of pemvidutide in alcohol use disorder (AUD) met its primary endpoint, showing a statistically significant reduction in heavy drinking days versus placebo.
Key secondary endpoints were also achieved, including a two-level reduction in WHO Risk Drinking Levels and zero heavy drinking days, both recognized by the FDA as registrational endpoints.
Pemvidutide demonstrated a favorable tolerability profile, with most adverse events being mild to moderate in severity.
Altimmune plans to request an End-of-Phase 2 meeting with the FDA based on these results.

The big picture

Altimmune's positive Phase 2 results for pemvidutide in AUD highlight the growing interest in dual-action therapies targeting both metabolic and behavioral aspects of the disorder. The company's strategic focus on liver diseases positions it well in a market where existing treatments have limited efficacy. The next steps will be crucial in determining whether pemvidutide can secure regulatory approval and address the significant unmet needs in AUD.

What we're watching

Regulatory Pathway: Whether the FDA will agree with Altimmune's proposed development and regulatory strategy for pemvidutide in AUD following the End-of-Phase 2 meeting.
Clinical Differentiation: How pemvidutide's dual glucagon/GLP-1 agonist mechanism will position it against existing treatments for AUD and its comorbidities.
Market Potential: The pace at which Altimmune can advance pemvidutide through Phase 3 trials and potential commercialization, given the substantial unmet need in AUD treatment.